论文部分内容阅读
目的:探讨托瑞米芬联合他莫昔芬应用于晚期乳腺癌的效果及对患者生存质量影响。方法:选择2010年1月—2014年1月80例晚期乳腺癌患者,将患者按完全数字表原则随机分为联合组与NP组,各40例。NP组使用常规NP化疗方案治疗,联合组在NP组基础上联合托瑞米芬及他莫昔芬治疗。对比两组患者近期治疗有效率、健康相关的生存质量和毒副反应。结果:联合组患者化疗有效率为70.00%,明显高于NP组的50.00%(P<0.01);联合组和NP组治疗后健康相关的生存质量评分较治疗前均有明显改善,差异有统计学意义(P<0.05);联合组治疗后健康相关的生存质量评分为(88.34±7.05)分,改善明显优于NP组的(80.84±5.94)分(P<0.01);联合组毒副反应(III~IV度)便秘、恶心呕吐、白细胞降低、粒细胞减少、血小板减少、肝肾功能异常发生率与NP组比较差异均无统计学意义(P>0.05)。结论:晚期乳腺癌患者化疗中,内分泌药物托瑞米芬联合他莫昔芬辅助治疗可以提升治疗效果,改善患者生活质量,值得临床推广应用。
Objective: To investigate the effect of toremifene in combination with tamoxifen on advanced breast cancer and its impact on the quality of life of patients. Methods: From January 2010 to January 2014, 80 patients with advanced breast cancer were selected. The patients were randomly divided into the combined group and the NP group according to the principle of complete digital meter (40 cases). NP group was treated with conventional NP chemotherapy. The combined group was treated with toremifene and tamoxifen on the basis of NP group. Short-term treatment efficiency, health-related quality of life and toxicity were compared between the two groups. Results: The effective rate of chemotherapy in combined group was 70.00%, which was significantly higher than that in NP group (P <0.01). The health-related quality of life scores of combined group and NP group were significantly improved after treatment (P <0.05). The health-related quality-of-life scores of the combination group were (88.34 ± 7.05) and significantly better than those of the NP group (80.84 ± 5.94) (P <0.01) (III ~ IV degrees). The incidence of constipation, nausea and vomiting, leukopenia, neutropenia, thrombocytopenia, liver and kidney dysfunction were not significantly different from those in NP group (P> 0.05). Conclusion: In the chemotherapy of patients with advanced breast cancer, the adjuvant therapy of endocrine drug toremifene and tamoxifen can improve the therapeutic effect and improve the quality of life of patients, which is worthy of clinical application.